Cardiovascular diseases claim 17.7 million lives annually, and account for 31% of all global deaths. Cardiovascular diseases can broadly be divided into the following types: i) hypertensive heart diseases, ii) coronary heart diseases, iii) inflammatory heart disease, iv) rheumatic heart diseases, v) stroke and vi) other cardiovascular diseases.
Following the publication of our recent Technology Landscape study on CRISPR-Cas9, MaxVal announces the latest advanced publication on the genome editing system, CRISPR, which has become an extremely important tool in medical research. The demonstration of the reprogrammable nature of Cas9 served as a catalyst to widespread adoption of CRISPR systems in biomedical and agricultural research. The potential benefits of CRISPR gene editing in several challenging diseases such as Alzheimer’s, cancer, and numerous autoimmune diseases are being explored by researchers.
Although CRISPR was known to have an important role in bacterial immunity for over a decade, it is only in the last 5 years that it has garnered interest as a gene editing tool. Increasing investment in this field is indicative of global market opportunities for CRISPR-Cas9 over existing alternatives.
IP strategists suggest that having a right strategy in place right from the outset of invention disclosure will help companies cut down their overall patent maintenance costs. With a little planning and preparation, you can learn how to manage your costs and achieve significant savings. Established companies, regardless of their assets or market values, look for every possible way to reduce direct and indirect costs.
Huge sums of time and money are invested to support ongoing research and development efforts globally, particularly in the most innovative industries like pharma, healthcare and biotechnology. The global R&D spending  is at a record high of US$1.7 trillion of which 80% of total spending is only from the Top 10 countries.
It’s been a busy year for mergers and acquisitions, with a number of billion dollar deals that happened. We tracked and analyzed over 700 Mergers & Acquisitions that occurred in 2017 and extracted the 20 largest deals across 9 industries, valued above $5 B.
Patent Term Adjustments (PTAs) alter the patent term and are meant to account for delays in patent prosecution, and usually increase the life of the patent beyond their normal 20 year term. They are usually calculated by accounting for prosecution delays by both the applicant and the USPTO. The PTO automatically grants adjustments, but patentees can petition to recalculate the adjustment if they disagree with the PTO's calculation.
The artificial intelligence (AI) landscape is growing quickly. Artificial intelligence startups raised $5B in 2016, a 10-fold increase since 2012. Tech giants (Google, Microsoft, IBM) are contributing heavily to this acceleration, both in academic and practical pursuits. Google published 218 papers on machine learning in 2016, nearly double the number of publications in 2014. In December 2016, Microsoft launched a new venture fund specifically to evaluate and fund AI startups, kicking off the fund with an investment in Element AI, then acquiring Maluuba just one month later.  
MaxVal, a leading technology-enabled IP solutions provider known for its cutting edge products and automated solutions announces the global data expansion of MaxVal’s Litigation Databank with the inclusion of valuable non-US litigation data.
When a Notice of Allowance (NOA) is received by the Applicant, it means that a patent application will no longer be reviewed by the examiner and it is entitled to the patent under the law. In other words, an application is about to be issued after the prosecution phase.